USPTO Patent Applications - Biotech (C12N)

Methods and Compositions for Designing and Selecting TinyRNAs to Maximize Target Cleavage

USPTO published patent application US20260098266A1 by Kotaro NAKANISHI disclosing methods for designing and selecting tinyRNAs with guide RNA and Argonaute molecules for gene expression regulation in biotherapeutic and diagnostic applications. The application was filed April 1, 2024, and published April 9, 2026.

Modified siRNA Targeting C9orf72 Gene for Neurological Disorder Treatment

USPTO published patent application US20260098264A1 for modified single- or double-stranded siRNA molecules targeting the C9orf72 gene for treatment of neurological disorders including amyotrophic lateral sclerosis and frontotemporal dementia. The application covers branched siRNA structures with nucleoside modifications, phosphorus stabilizing moieties, and methods for CNS delivery.

Genentech Modified CHO Cells for Therapeutic Protein Production

USPTO published patent application US20260098254A1 by Genentech, Inc. covering modified CHO cells for therapeutic protein production. The application claims methods, cells, and compositions where mammalian cells have reduced or eliminated activity of host cell proteins including lipases, esterases, and hydrolases. Application No. 19408114 was filed December 3, 2025.

siRNA Molecules Targeting ATXN3 Gene for Spinocerebellar Ataxia Treatment

The USPTO published patent application US20260098265A1 disclosing single- or double-stranded siRNA molecules targeting the ataxin-3 (ATXN3) gene for treatment of spinocerebellar ataxias, including spinocerebellar ataxia type 3. The application includes branched siRNA designs (di-branched, tri-branched, tetra-branched) with nucleoside modifications, 5' phosphorus stabilizing moieties, and methods for CNS delivery. The application was filed on September 28, 2023.

CRISPR/Cas9 Gene Editing Method for Beta-Amyloid Pathway Attenuation

USPTO published patent application US20260097136A1 filed by Wisconsin Alumni Research Foundation on November 12, 2025. The application covers CRISPR/Cas9 constructs designed for C-terminal truncation of human amyloid precursor protein (APP) to attenuate the beta-amyloid pathway implicated in Alzheimer's disease, along with methods of making and using such constructs. The publication provides public notice of the claimed gene-editing technology and its potential therapeutic applications in neurodegenerative disease. No enforceable rights are granted until a patent issues following examination.

CRISPR/Cpf1 Gene Editing Systems Using Recombinant AsCpf1 and LbCpf1 crRNA

The USPTO published patent application US20260098249A1 for Integrated DNA Technologies covering recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for CRISPR/Cpf1 endonuclease gene editing systems in mammalian cell lines. The application includes ribonucleoprotein complexes using length-truncated, chemically-modified, or dual-modified AsCpf1 crRNAs and methods for performing gene editing using these systems.

Cells, Organs with Modified Genes for Xenograft Tolerance

Cells, Organs with Modified Genes for Xenograft Tolerance

Cre-Lox AAV Gene Therapy Reconstitution System for Large Gene Delivery

The USPTO published patent application US20260098279A1 for a Cre-Lox AAV gene therapy system enabling delivery of therapeutic genes up to 16kb using up to four adeno-associated virus vectors with sequence-specific recombination. The invention by inventor Seongjin Seo includes novel lox site embodiments for near-unidirectional recombination. Applications include treatment of genetic disorders such as IFT140-associated retinitis pigmentosa and other retinal degeneration conditions.

Low Dose Psilocybin in Foodstuff and Microbes for Same

USPTO published patent application US20260098286A1 by ATX PHARMERS LLC covering engineered microbes transformed with psilocybin genes under weak or medium-level promoters to produce low levels of psilocybin, with applications in microdose and sub-microdose foodstuff production. No compliance obligations or deadlines are imposed by this publication.

Compositions and Methods for Screening Mutations in Thyroid Cancer

The USPTO published patent application US20260098297A1 on April 9, 2026, disclosing methods for screening mutations in thyroid cancer to determine whether patients with indeterminate thyroid nodules should undergo diagnostic surgery. The application covers screening patient thyroid nodules and detecting alterations in target nucleic acid sequences corresponding to thyroid cancer-related genes. Six inventors are named including Shih-Min Cheng, Joseph Catanese, and Andrew Grupe. Filing date was December 9, 2025.

Affinity Chromatography Column for Cell Binding

USPTO published patent application US20260098840A1 by TQ Therapeutics GmbH for a column design for affinity chromatography. The invention comprises a column body with a retention volume containing a stationary phase, open ends for cell addition/removal, and obstacles such as grids or pins. The application covers the column design, a system of columns, and methods for binding cells using the disclosed technology.

T Cell Function Modulation Using CRISPR-Cas Epigenetic Systems

T Cell Function Modulation Using CRISPR-Cas Epigenetic Systems

Recombinant AAV Vectors for Treating Muscular Dystrophy

USPTO published patent application US20260097132A1 assigned to Sarepta Therapeutics, Inc. covering recombinant adeno-associated virus (rAAV) vectors for expressing human micro-dystrophin gene to treat muscular dystrophy, including Duchenne Muscular Dystrophy. The application includes methods for genotyping DMD gene to determine rAAV gene therapy contraindications. Filing date was September 22, 2023.

Mammoth Biosciences CRISPR Dystrophin Editing Patent Application

USPTO published patent application US20260097134A1 assigned to Mammoth Biosciences, Inc. covering CRISPR-Cas systems and methods for editing human dystrophin genes to treat Duchenne muscular dystrophy (DMD). The application includes compact Type V CRISPR-associated proteins, RNA-dependent DNA polymerase, and guide nucleic acids for gene modification therapies.

Fungal Spore Production Method Using Dual Liquid Medium

The USPTO published patent application US20260098242A1 covering a method for producing fungal spores using a dual liquid medium system. The first medium has a lower carbon content than the second medium. Inventors: Van De Zilver Eric, Laurens Van Leeuwen. Application filed September 26, 2023; published April 9, 2026.

Recombinant Yeast with Sucrose-Inducible Promoter for Target Protein Expression

USPTO published patent application US20260098241A1 assigned to FUJIFILM Corporation covering recombinant yeast strains containing sucrose-inducible promoters for highly expressing target proteins without methanol, along with production methods and kits.

Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes

Herpesvirus Intestinal Treatment Prevents Neurodegeneration via Exosomes

Selective Astrocytic MAGL Inactivation for Alzheimer's Disease Treatment

USPTO published patent application US20260098268A1 for compositions and methods treating Alzheimer's disease through selective astrocytic MAGL inactivation via AAV-mediated gene silencing. Inventors: Chu Chen, Jian Zhang. Filed September 29, 2023. The invention targets neuroinflammation reduction by selectively inactivating MAGL in astrocytes rather than globally, minimizing adverse effects from neuronal 2-AG degradation disruption.

siRNA Compositions Targeting CD33 Gene for Neuroinflammatory Disease Treatment

The USPTO published patent application US20260098269A1 covering single- or double-stranded interfering RNA (siRNA) molecules targeting the Siglec-5 (CD33) gene, pharmaceutical compositions containing these molecules, and methods for treating neuroinflammatory diseases including Alzheimer's disease. The application claims specific nucleoside modifications, internucleoside linkage modifications, branched siRNA configurations (di-branched, tri-branched, tetra-branched), 5′ phosphorus stabilizing moieties, hydrophobic moieties, and CNS delivery methods.

Multivalent Trident Aptamers for Molecular Recognition

The USPTO published patent application US20260098270A1 by McMaster University on April 9, 2026. The application covers multivalent trident aptamers comprising a branched linker molecule with 2-3 variable arms connected to a root, designed for enhanced affinity and avidity in target molecular recognition. The aptamers have applications in pharmaceutical, diagnostic, and therapeutic fields.

Method for Increasing Recombinant Protein Expression

The USPTO published patent application US20260098271A1 assigned to Hoffmann-La Roche Inc., covering a method for increasing recombinant protein expression through use of a nucleic acid encoding a selection marker, self-cleaving peptide sequence, and proteinaceous protease inhibitor. The invention aims to increase heterologous polypeptide production by reducing protease cleavage. The application was filed on May 20, 2025.

Methods for Transgenerational Genome Editing in Plants

The USPTO published patent application US20260098272A1 for methods of transgenerational genome editing in plants. The application discloses nucleic acid constructs encoding RNA-guided nucleases under constitutive promoters combined with guide RNAs for editing plant genomes across generations. Inventors include Giane Balser, Lisa Kanizay, Ramanjot Kaur, Thomas Scott Ream, Zarir Vaghchhipawala, and Chenxi Wu. The application was filed on October 6, 2025, under application number 19350752.

M13 Phage Engineered to Capture SARS-CoV-2 Virus

M13 Phage Engineered to Capture SARS-CoV-2 Virus

Mapping and Modification of Gene Network Endophenotypes

The USPTO published patent application US20260100246A1 by Inari Agriculture Technology, Inc., disclosing a machine learning method for predicting endophenotypes of interacting partner genes. The method partitions endophenotype profiles into two sets, modifies one set to a desired level, and uses a trained ML model to predict resulting changes in the unmodified set. The invention enables targeted modification of gene networks to achieve desired agricultural traits.

Erythroid Lineages from Pluripotent Cells

USPTO published patent application US20260097074A1 by Dhvanit Shah disclosing methods for generating hematopoietic lineages including erythroid progenitor cells, progenitor erythroblasts, and erythroid cells from human induced pluripotent stem cells (iPSCs) for cell therapy applications. The application covers efficient ex vivo processes for developing these lineages and isolated cell compositions produced by the methods.

Method to Change Tumor Associated Macrophage Polarization Using Magnetosomes and Radiation

USPTO published patent application US20260097075A1 by Université Paris Cité for a method to change tumor-associated macrophage polarization by exposing macrophages to magnetosomes and radiation. The invention aims to shift macrophages from M0 or Mi polarization to Mj polarization for potential cancer immunotherapy applications.

Modified Gamma Delta T Cells for Cancer Therapy

USPTO published patent application US20260097077A1 for a method of treating cancer using gamma delta T cells modified with XBP1 gene or protein inhibitors. The modified T cells demonstrate enhanced antitumor activity in tumor microenvironments with endoplasmic reticulum stress. Inventors are Minkyung Song, Hocheol Shin, and Ji Yun Park, with application filed September 4, 2025.

Cell Behavior Control Methods Without Genetic Modification

USPTO published patent application US20260097078A1 by inventors Victor TETS and Georgy TETS covering products and methods for managing cell behavior, cell memory, and erasure of cell memory without genetic modification. The application relates to therapeutic, diagnostic, agricultural, and biomanufacturing applications. The invention distinguishes itself from prior art by enabling control of cellular properties without mutagens, gene introduction, or environmental condition changes.

Removing Endogenous TCR Chains for Enhanced TCR-Based Immunotherapies

USPTO published patent application US20260097079A1 by Khosravi Maharlooei et al. disclosing methods for treating diseases using adoptive cell therapy with modified lymphocytes having inactivated endogenous TCRα and TCRβ chains. The application covers compositions and methods for enhanced TCR-based immunotherapies.

Exosomes from Mesenchymal Stem Cells for Alzheimer's Treatment

USPTO published patent application US20260097080A1 covering exosomes isolated from mesenchymal stem cells for reducing inflammation and treating Alzheimer's disease. The application claims exosomes exposed to conditioned media with microglial cells in the presence of LPS or beta-amyloid oligomer. This is a publication of a pending application, not a granted patent.

Low-Temperature Preservation Cabinet with Temperature Isolation for Biological Samples

USPTO published patent application US20260092260A1 by Genepoint Technologies (Shanghai) Co., Ltd. for a low-temperature preservation cabinet designed for biological samples, featuring a storage region, equipment region, and temperature isolation zone between them. The filing date was December 8, 2025, with application number 19412761.

Cell Adhesion System for Interspecies Chimeras

USPTO published patent application US20260092259A1 by inventors Jun Wu, Emily B. Ballard, and Jia Huang for a cell adhesion system enabling formation of interspecies chimeras through engineered cells expressing antigen-binding proteins or antigens with cell membrane signaling peptides. The invention facilitates generation of organs, organoids, or tissue masses from human and non-human chimeric animals for potential transplant applications.

Glucosyltransferase Mutant Converting Rebaudioside D to Rebaudioside M

USPTO published patent application US20260092262A1 for Shandong Benyue Biological Technology Co., Ltd covering a glucosyltransferase mutant enzyme that catalyzes conversion of Rebaudioside D (RD) to Rebaudioside M (RM). The mutant contains specific amino acid substitutions at positions 84, 88, 126, 196, and 379 and exhibits significantly higher enzyme activity than wild-type variants. The application was filed September 26, 2025.

Bacteriophage structural proteins via cell-free expression system

The USPTO published patent application US20260092261A1 for multi-peptide structures comprising heterologous functional sites derived from bacteriophage structural proteins produced via cell-free expression. The application, filed by Elisabeth Falgenhauer and co-inventors Friedrich Simmel, Kilian Vogele, and Sophie von Schönberg, covers compositions and methods for universal anti-microbial applications in medicine, chemistry, biotechnology, agriculture, and food industry.

Double Tagged Serratia Marcescens Nuclease Patent Application

USPTO published patent application US20260092265A1 for a double-tagged Serratia Marcescens Nuclease (SMN) engineered with a C-terminal Chitin Binding Domain (CBD-tag) and a 6-mer poly-histidine tag connected by a Gly-Ser linker. Inventors: Dapeng Sun, Aine Quimby, Zhenyu Zhu. Application No. 19324955 was filed September 10, 2025.

Modified GlcNAc-1-Phosphotransferase sequences, patent application

USPTO published patent application US20260092263A1 for modified, truncated GlcNAc-1-Phosphotransferase (PTase) amino acid sequences that retain phosphotransferase activity. The application, filed August 4, 2025 (Application No. 19289364), covers truncated PTase forms lacking or with modified linkers and/or lacking the C-terminal transmembrane and cytosolic domain, demonstrating retained ability to phosphorylate lysosomal or non-lysosomal target proteins.

CRISPR Enzymes and Systems

The USPTO published patent application US20260092266A1 by Feng Zhang et al. for engineered CRISPR-Cas systems comprising multimeric complexes with β-CASP polypeptides and small Type II-B, II-C, and II-D Cas proteins for modifying target polynucleotides. The application (No. 19388533) was filed November 13, 2025, and published April 2, 2026.

Fusion protein complexes for epigenetic regulation, cancer treatment

USPTO published patent application US20260092267A1 by inventors Seung Ja Oh and Na Ly Tran for fusion protein complexes including transcription enhancers and dCas9 proteins for epigenetic regulation. The application covers complexes with guide RNAs (gRNAs) for inducing apoptosis of colorectal cancer cells and compensating for rhodopsin deficiency to treat ocular diseases.

Methods for Generating Hematopoietic Progenitor Cells

The USPTO published patent application US20260092257A1 covering methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells using chemically-defined culture media. The application was filed October 2, 2025, under Application No. 19347888. Inventors include Angelica Gomes Ueltschy and Michael Elias.

Pepmixes for Multiviral CTL Generation

USPTO published patent application US20260092256A1 by Baylor College of Medicine covering methods of generating CTLs (cytotoxic T lymphocytes) targeting antigens from multiple viruses. The invention uses peptide mixtures exposed to PBMCs with IL4 and IL7 expansion. Published April 2, 2026, Application No. 19020866.

Phase-Changing Matrix for 3D Organoid Culture with Mesenchymal Stem Cells

The USPTO published Application US20260092254A1 claiming a composition for three-dimensional cell and organoid culture comprising a phase-changing matrix with partially ordered polypeptide encapsulating bone-marrow derived or adipose-derived mesenchymal stem cells. The application was filed on September 21, 2023 (Application No. 19113814). This publication provides public notice of the claimed invention for examination purposes.

ALT-803 IL-15 Soluble Fusion Molecules and Methods

The USPTO published patent application US20260092097A1 for ALT-803, a complex of interleukin-15 (IL-15) superagonist mutant and dimeric IL-15 receptor α/Fc fusion protein. The application covers compositions and methods for enhancing immune response against neoplasia (multiple myeloma, melanoma, lymphoma) or viral infections (HIV). Inventors: Hing C. Wong, Peter Rhode, Bai Liu, Xiaoyun Zhu, Kai-Ping Han. Application filed June 25, 2025.

Cell Based Assays for Botulinum Neurotoxins Serotype-Specific

USPTO published patent application US20260092255A1 for serotype-specific cell-based assays used in characterizing Clostridia botulinum neurotoxins. The assays utilize genetically modified cells capable of discriminating between different serotypes of clostridium neurotoxins without requiring serotype-specific neutralizing antibodies or competing heavy chains. Inventors: Ward Tucker, Francis Mark Dunning, Tim Piazza. Application No. 18920316.

Methods of Recellularizing Tissue Transplant for Improved Transplantability

The USPTO published patent application US20260092253A1 for methods of recellularizing an organ or tissue matrix for improved transplantability. Inventors are Doris A. Taylor and Stefan M. Kren. The application was filed December 9, 2025, under application number 19413394. This publication provides public notice of the pending patent application but does not grant any patent rights.

Oncolytic Herpes Virus Cancer Therapy Vectors

USPTO published patent application US20260091069A1 for an oncolytic herpes simplex virus vector with dual transcriptional and translational control for cancer therapy. The vector incorporates modified ICP27 and ICP34.5 genes under CEA promoter and miRNA-124/143 control respectively, and includes a virus-expressed cytokine cassette encoding IL-12 and IL-15/IL-15RA. Inventors include William Wei-Guo Jia, Dmitry V. Chouljenko, and six others.

Methods for Improving Cognitive Function Using ILC2 Cranium Implants

The USPTO published patent application US20260091063A1 by Albany Medical College covering methods to improve cognitive function by implanting activated group-2 innate lymphoid cells (ILC2) into a subject's cranium. The application also discloses methods using cytokines including IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin to treat aging-associated cognitive decline. Assignee: Albany Medical College; Inventors: Qi Yang; Application No. 19335390.

MicroRNA from Rhodiola for Fibroplasia Treatment

USPTO published patent application US20260091052A1 filed by Beijing Baishihekang Pharmaceutical Technology covering microRNA derived from Rhodiola root for prevention and treatment of fibroplasia medical signs and syndromes. The application (No. 19319016) was filed September 4, 2025 and published April 2, 2026, listing five inventors including Chengyu Jiang and Jianchao Du. CPC classifications indicate pharmaceutical compositions and nucleic acid technologies.

TSLP Treatment Using Oligonucleotide siRNA and ASO Compositions

The USPTO published patent application US20260091053A1 disclosing oligonucleotide compositions (siRNA and antisense oligonucleotides) targeting Thymic Stromal Lymphopoietin (TSLP) for treatment of TSLP-related diseases. The application covers methods of treating airway disorders by administering oligonucleotides specific to the long isoform of TSLP. Inventors include Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, and David Rozema. The application was filed on May 19, 2025.

Rod-Derived Cone Viability Factor Fusion Protein

USPTO published patent application US20260091133A1 disclosing a fusion protein comprising rod-derived cone viability factor-S (RdCVF-S), a hydrophilic peptide, and a signal peptide. The invention covers encoding nucleic acids, viral vectors, and pharmaceutical compositions for potential treatment of ocular conditions. Inventors: Tianci LUO, Daniel LIPUT, Fong Qi LIANG. Application No. 19339969 filed September 25, 2025.

Recombinant AAV Vectors for Treating Proteinopathies in CNS

The USPTO published patent application US20260091134A1 by Shanghai Vitalgen Biopharma Co., Ltd. covering recombinant adeno-associated viral (rAAV) vectors encoding Progranulin (PGRN) and/or Stathmin-2 (STMN2) for treating proteinopathies in the central nervous system. The application, filed November 26, 2025 (Application No. 19401460), includes codon-optimized coding sequences and viral particle compositions.